Relier Pairs Diabetes Oral MedsVersion en ligne NUr115 Oral Diabetic Agents par Concetta Fiorentino 1 Prevents kidneys from reabsorbing glucose. 2 Possible side-effect of impaired platelet function. 3 Drug to drug interaction with NSAIDS. 4 Sensitize body tissue to insulin: stimulates insulin receptor sites. 5 Inhibit production of glucose by the liver. 6 Stimulate pancreas to secrete insulin. 7 Stimulate beta cells of the pancreas. 8 Do not increased insulin secretion. 9 Usually given once a day. 10 Increase and prolong the action of the hormone that increases insulin release and decreases glucagon levels. 11 Enhances glucose-dependent insulin secretion. Non-sulfonylurea insulin secretagogues (repaglinide/Prandin, nateglinide/Starlix) Biguanides (metformin (Glucophage) Metformin with glyburide (Glucovance) Second generation sulfonylureas (glipizide (Glucotrol) Glyburide (DiaBeta) Glimepiride (Amaryl) Alpha-glucosidase inhibitors (acarbose/Precose, miglitol (Glyset) Avandia Sodium-glucose co-transporter 2 inhibitors (empagliflozin/Jardiance glipizide Dipeptidyl Pepidase-4 Inhibitors (sitagliptin/Januvia, vildagliptin /Galvus) Januvia Glucagon-like peptide-1 agonist (liraglutide/Victoza,, dulaglutide/Trulicity) Thiazolidinediones (pioglitazone (actos, rosiglitazone/Avandia)
Créer jeu